Medicine Matters oncology

Incidence: Rarely severe, hypothyroidism is induced by anti-PD-1, -PD-L1 and -CTLA4 therapies with an overall incidence estimated to be 6.6%, although incidence is highest with combination therapy, followed by anti-PD-1 or -PD-L1 monotherapy, then anti-CTLA4 monotherapy [2].

Onset: Typical onset is usually from 7 weeks with CTLA4 blockade and from 10 weeks in anti-PD-1 therapy [3].